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Abstract
Objective. Longer life expectancy has resulted in people living with an increasing number of
co-morbidities. The average individual with inflammatory arthritis has two co-morbidities, which
contribute to higher mortality, poorer functional outcomes and increased health-care utilization and
cost. A number of studies have investigated the prevalence of co-morbidities, whereas this study was
designed to look at patient perspectives.
Methods. The study comprised two parts: a patient questionnaire and an interview. Individuals with
physician-verified inflammatory arthritis along with one or more Charlson co-morbidities were invited to
participate. In-depth data were obtained by interviews with 12 willing participants.
Results. One hundred and forty-six individuals were recruited; 50 (35%) had one co-morbidity, 69
(48%) had two and 25 (17%) had more than four co-morbidities. Seventy-seven individuals (53%)
reported that co-morbidities affected their health as much as their arthritis, and 82 (56%) reported
dependence on others for activities of daily living. Lack of education was highlighted by 106 (73%)
participants. Qualitative data provided further support for the challenges, with participants highlighting
the lack of time to discuss complex or multiple problems, with no-one coordinating their care. This, in
turn, led to polypharmacy and insufficient discussion around drug and disease interactions, complica-
tions and self-help measures.
Conclusion. This study highlights the challenges for individuals with inflammatory arthritis who suffer
with multiple co-morbidities. The challenges result from limited resources or support within the current
health-care environments. Individuals highlighted the poor quality of life, which is multifactorial, and the
need for better educational strategies and coordination of care to improve outcomes.
Key words: co-morbidities, Charlson co-morbidity, inflammatory arthritis, polypharmacy, patient perception,
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Key messages
. Individuals with inflammatory arthritis can have multiple co-existing conditions with different levels of severity,
which need to be taken into account.
. Individuals with inflammatory arthritis reported a range of perceptions about co-morbidities and support
preferences.
. Recommendations made by the individuals in this study align with EULAR guidelines on education.
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Introduction
With advances in treatments, remission and improved
survival are not only an achievable goal, but a quality
target. As a result of living longer and suffering with a
chronic inflammatory disease, individuals with inflamma-
tory arthritis have a higher risk of co-morbidities, such
as cardiovascular diseases, osteoporosis, depression,
infections and cancer [1–4]. Currently, the average
sufferer of inflammatory arthritis has two or more co-
morbid disorders, which contribute to a higher mortality
[2, 5–12]. Improvements in pharmacotherapy result in
better functional outcome owing to improved disease
control, but co-morbidities might reverse this benefit
[13]. Higher numbers of co-morbidities result in greater
utilization of health-care resources [14]. RA is also
known to result in greater societal costs [15, 16], esti-
mated as e780 million per year in England [17].
Treatment of co-morbidities is challenging. Current
guidelines for managing rheumatic diseases do not
consider health economics, patient perspectives and the
medical impact of the inevitable polypharmacy and
interacting medical conditions. There are some data on
measurement of co-morbidity and impact on outcomes
[2, 4, 7, 13, 14]. However, there is little evidence regard-
ing patient perspectives about living with multiple condi-
tions or how their perspectives relate to professional
concepts. If a health-care system is to provide holistic
care, we need a better understanding of these relation-
ships. The aim of this study was to explore the individ-
ual experience and understanding of co-morbidities and
to understand the impact of these co-morbidities on
quality of life and activities of daily living.
Methods
Setting
Prospective recruitment was carried out in three UK
Rheumatology departments: Southend University
Hospital, Norwich and Norfolk University Hospital NHS
Foundation Trust and University Hospital Coventry &
Warwickshire Hospitals NHS Trust.
Participants
Individuals with a physician-verified diagnosis of inflam-
matory arthritis and with one or more Charlson
co-morbidity were identified by clinicians from routine
outpatient clinic attendances. Recruitment commenced
in June 2018 and was restricted to an estimated 150
participants, because of expected data saturation.
Questionnaire
After informed written consent, the participants were in-
vited to complete a questionnaire either at home or in
the outpatient department. The survey comprised 26
questions divided into four broad themes
(Supplementary Data S1, available at Rheumatology
Advances in Practice online): demographics, disease-
related factors and Charlson co-morbidities; awareness
and impact of co-morbidities on quality of life; polyphar-
macy and treatment perception; and lifestyle.
Interviews
In the survey, the participants were invited to express
willingness to participate in a semi-structured interview.
Twelve participants were chosen deliberately (to include
demographics, conditions and co-morbidities) to collect
complementary in-depth information. We stopped the
interviews when thematic saturation was achieved. The
interview questions were open ended and covered
topics including the impact of Charlson co-morbidities
on their quality of life, strategies adopted to manage
multiple conditions, patient experience of polypharmacy,
barriers to exercise and lifestyle changes, and expecta-
tion of services (Supplementary Data S2, available at
Rheumatology Advances in Practice online). The ques-
tionnaire items were derived from discussion, literature
review and discussion with patient representatives from
a national patient charity.
All interviews were digitally audiotaped, with interviews
lasting between 45 and 60 min. Interviewees were also
given the time to provide additional comments they
thought were relevant to the topics discussed. Interviews
were transcribed verbatim by an independent transcribing
company (Transcription agency LLP, Hythe, Kent, UK).
Data were analysed using a combination of inductive and
deductive techniques. Initial analytical summaries of the
interviews were organized by labelling data relevant to
each of the questions in a thematic approach
(Supplementary Data S3, available at Rheumatology
Advances in Practice online). This was undertaken inde-
pendently by G.M.K., F.H. and N.J.G. Any discrepancies
in coding were resolved by discussion. Similar concepts
brought up by different participants were studied in
greater detail, leading to the identification of key themes.
Individual recommendations on service improvement were
also elicited.
Ethics
Ethical approval for this study was granted by the North
London Research Ethics Committee (REC reference: 18/
LO/0409), and all participants gave written informed
consent.
Statistical analysis
Data were analysed using Excel. Categorical data are
summarized as counts and percentages, and age is pre-
sented as the mean and median.
Results
One hundred and forty-six of 194 invited individuals
completed the questionnaire (75% response rate). One
hundred and four (71%) had RA, 30 (21%) had PsA, and
12 (8%) had axial spondyloarthritis. Demographics
and disease characteristics are summarized in
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Supplementary Tables S1 and S2, available at
Rheumatology Advances in Practice online. Fifty (35%)
had one Charlson co-morbidity, 69 (48%) had two, and
25 (17%) had more than four Charlson co-morbidities.
The most common co-morbidities were hypertension [75
(51%)], pulmonary disease [49 (34%)], diabetes mellitus
[35 (24%)], ischaemic heart disease [21 (14%)], cancer
[20 (14%)] and transient ischaemic attack [11 (8%)].
Eighty-four (58%) of the respondents were >60 years
old. Most respondents were retired [85 (58%)], and 31
(21%) had to cut down working hours because of the
co-morbidities. The majority of respondents self-
reported the severity of rheumatic disease as either
moderate [61 (42%)] or severe [35 (24%)].
Awareness and impact of co-morbidities
Seventy-seven (53%) reported that Charlson co-
morbidities affected their health as much as their
arthritis. Seventy (48%) said that they received detailed
information about arthritis/Charlson co-morbidities
(Supplementary Table S3, available at Rheumatology
Advances in Practice online). Seventy-two (49%) of the
cohort were not aware that Charlson co-morbidities can
be caused by medications or complications of arthritis.
Eighty-two (56%) of the respondents were more or less
dependent on their family members or carers for their
activities of daily living. Of those, three-quarters needed
help at least twice a week.
Current therapy, efficacy and their involvement in
treatment decisions
Overall, 48 (33%) used an NSAID for arthritis, and 73
(50%) used other analgesics, such as paracetamol,
opiates or neuromodulators. One hundred and four
(71%) used DMARDs, 41 (28%) biologics and 32 (22%)
CSs. One hundred and three (71%) were taking medica-
tions for other co-morbid conditions (Supplementary
Table S4, available at Rheumatology Advances in
Practice online). Most respondents [100 (68%)] rated
treatment efficacy as sufficiently effective (i.e. improve-
ment), and consistent with this, 43 (29%) reported re-
markable improvement and 57 (39%) some
improvement. Only six (4%) reported worsening of their
inflammatory arthritis. In 17 (12%) individuals, arthritis
improved but they developed side-effects, and 7 (5%)
required medications to counteract those side-effects.
The overall involvement of respondents in their treat-
ment decisions was 107 (73%). Thirty-five (24%) felt that
the involvement was minimal. Thirty-two (22%) felt that
they were insufficiently, but somewhat, involved in
decision-making, and 38 (26%) reported no involvement
at all. In contrast, 39 (27%) reported feeling ‘very much’
involved in treatment decisions. One hundred and six-
teen (80%) of the respondents said the doctors
reviewed their medications at regular follow-ups and
had discussed benefits and risks of each treatment. The
majority were compliant with arthritis and non-arthritis
medications.
Lifestyle advice and benefits of lifestyle changes
Lack of education was reported by 106 (73%)
(Supplementary Table S5, available at Rheumatology
Advances in Practice online). Also, 43 (30%) individuals
had not received any advice on BMI and were not aware
of associations between obesity and OA or diabetes, hy-
pertension or heart disease. Likewise, 17 (12%) had not
received advice on alcohol and its ill effects. Ninety-five
(65%) said they were advised about health benefits of
exercise, but 31 (21%) did not exercise in any form. The
main reasons for not taking exercise were pain, fatigue,
lack of energy, lack of motivation, low morale, fear
avoidance and co-morbid conditions. Most took light
exercise, such as walking, gardening, tai chi and pilates.
Interviews
Data from interviews paralleled the survey results, indi-
cating the need for education and interventions to ad-
dress lifestyle changes, polypharmacy and strategies to
manage multiple conditions. Individuals were also asked
how they would like services to develop in future to help
their co-morbidity management better.
Access to health care
Most preferred to access care from multiple specialists.
Some felt strongly that their general practitioner (GP)
should be the main co-ordinator, but others felt that
GPs did not have time for complex or multiple problems
or had felt trapped because their GP/hospital had sug-
gested review by each other. A number of individuals
expressed frustration in not receiving timely access to
health care and were affected by poor communication
between the professionals supervising various aspects
of their health care. Some individuals suggested that
more time is needed for multiple problems and that
there is a need for better oversight of the individual
rather than separate conditions, because a single ap-
proach does not fit all.
Awareness and impact of co-morbidities, themes
and quotes
Quotes can be found in Fig. 1. Individuals described
how multiple conditions were burdensome, caused con-
fusion, and they were often unsure which condition was
flaring. They were given opposite advice from different
specialists. Many indicated that they were unaware that
multiple conditions and drugs were interrelated or inter-
linked (e.g. CSs leading to diabetes). Some individuals
described how they had to find their own management
strategies by setting small goals and targets to manage
Charlson co-morbidities and polypharmacy. Individuals
described how co-morbidity had a significant impact on
their family life, psychosocial life, employment and qual-
ity of life, in particular in the older age group.
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Polypharmacy and quotes
Quotes can be found in Fig. 1. Our results revealed that
understanding of polypharmacy is limited in most indi-
viduals. Some did not know why they were prescribed
so many drugs and were unsure whether the multiple
pills were effective. Many expressed concerns about
polypharmacy over time and the possible negative
impacts on their health. Given that different medications
ran out at different times, individuals often had difficulty
in remembering to order medications or renew their pre-
scription. Some of them used strategies such as an
alarm for warfarin and MTX, whereas others relied on
pill boxes, family members and diaries.
Lifestyle and quotes
Quotes can be found in Fig. 1. Many individuals said
they were aware of health benefits of exercise, weight
loss or stopping smoking but were not sure that lifestyle
change would help them personally. Fear avoidance
was a commonly mentioned reason stopping individuals
from being more active. They expressed lack of informa-
tion on how much exercise or what type of exercise was
safe for them. A few individuals reported difficulty adher-
ing to a healthy diet, in particular individuals with diabe-
tes or Crohn’s disease, and it took longer to do food
shopping. They indicated that they did not receive any
helpful advice regarding exercise or weight loss and
would like guidance from their medical professionals.
Discussion
To our knowledge, this is the first study to have
explored perspectives on co-morbidities from the
viewpoint of the individual suffering with them. We found
substantial co-morbidities in people with inflammatory
arthritis, most commonly hypertension, pulmonary
disease, diabetes mellitus, ischaemic heart disease
and cancer. These conditions affected their health as
much as their arthritis. Issues raised were the negative
impacts on quality of life, deterioration of physical func-
tion, strain on relationships and social life, helplessness,
multiple appointments with different specialties, lack of
clarity, psychological effects and employment issues.
Multimorbidity is reported in many chronic conditions,
including chronic renal disease, with a similar lack of
awareness that the index condition is associated with
additional conditions [17, 18]. A review of the experience
of individuals of coping with multimorbidity found similar
themes to our survey, namely the need for multiple con-
tacts with different health-care providers, negative emo-
tions, polypharmacy and coping in the social context
[19]. Our study echoes the findings of previous studies,
but in addition we highlight a wider problem that health
professionals face in providing effective information on
co-morbidity and providing holistic management, partic-
ularly in relatively short appointments at 6- to 12-month
intervals. There are international recommendations
about specific co-morbidities (e.g. cardiovascular risk in
RA [20]), but there are no recommendations regarding
the overall management of co-morbidities except for the
overarching principle that such cases need a tailored
approach. It is difficult to have a single model for as-
sessment and management of co-morbidities, and we
therefore need services to be delivered by a multidisci-
plinary team with representation of wide-ranging skills,
with clear and easy lines of communication between all
parties involved, as indicated by individuals in this study.
Multimorbidity is likely to increase over time and could
pose considerable challenges to health systems and
FIG. 1 Quotes relating to awareness and impact of co-morbidities, polypharmacy and lifestyle
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economies not equipped to care for complex conditions.
We need to develop new models of care and better
approaches to clinical management of individuals with
co-morbidities.
Participants in this study were divided in their views
with regard to who should provide holistic management.
In the UK, annual reviews and monitoring for co-
morbidities are recommended by the National Institute
for Health and Care Excellence [21], thus combining dis-
ease control and co-morbidity management as part of
the daily practice in inflammatory arthritis. Despite 66%
of participants self-reporting that they had moderate to
severe disease, 68% also reported that their treatments
were effective. This represents the major improvements
in modern rheumatology clinics following the treat-to-
target initiatives. Several studies have found that holistic
care, patient-centred information and communication
skills of nurses have improved outcomes [22–25].
Annual screening for specific co-morbidities, such as
cardiovascular risk, diabetes mellitus and osteoporosis,
using validated tools can also be delivered within pri-
mary care. One of the concerns identified by individuals
in our study was the lack of available information on the
management of co-morbidities. Current guidelines from
EULAR [20] state that the best care includes explicit pa-
tient involvement in treatment decisions, but some indi-
viduals in this study felt that they were insufficiently
involved in the decision-making process.
We have identified that most participants reported low
levels of physical activity, the reasons for which were
multifactorial. Reduced physical activity in RA is associ-
ated with disease activity, but also with obesity, poor
mental health and patient perception of disease [26–28].
We recommend the presence of a physiotherapist and
an occupational therapist in a multidisciplinary team,
which might allow these issues to be addressed in an
efficient and expedient manner. Traditionally, these roles
have been under-resourced, and we feel that it is crucial
for every rheumatology department to be staffed ade-
quately with these crucial resources.
Participants in our cohort were not aware of the dan-
gers of polypharmacy and drug or disease interactions.
Polypharmacy was associated with higher HAQ scores
and increased risk of adverse events [29]. Medication
reviews, vigilance for drug interaction and de-escalation
of medication could be handled by a hospital or com-
munity pharmacist. There are tools such as START
(Screening Tool to Alert doctors to Right Treatment) to
evaluate a patient’s medication [30] and STRIP
(Systematic Tool to Reduce Inappropriate Prescribing)
to manage prescribing and de-prescribing, which also
incorporates patient preferences [31]. These tools could
be incorporated into clinical decision support systems to
improve medication-related problems.
Our study also has limitations that we recognize. We
used a non-validated questionnaire, which did not allow
calibration of responses to any available metric. The ex-
ploratory single-group design and lack of control group
might have introduced bias.
Conclusions
This study has highlighted the interplay of co-morbidities
with inflammatory arthritis, which leads to a deterioration
in the quality of life, substantial disability and polyphar-
macy concerns. Individuals express the need for better
education, co-ordination and communication across spe-
cialties, longer appointments and timely access to health-
care resources. Services focused on the needs of these
individuals are imperative for improving quality of life.
Acknowledgements
This study was funded by Southend charity group, and
we thank the charitable committee. We thank all the
individuals for taking part in the study, and staff at the
Southend University Hospital, Norwich and Norfolk
University Hospital Foundation Trust, and University
Hospital Coventry and Warwickshire Hospitals NHS
Trust. We thank Southend University Hospital, Specialist
Nurses Anne Barton, Sunitha Achandil and Dawn
Chapman for secretarial support. We thank Norfolk and
Norwich University Hospital NHS Trust, Research
Assistant James Kennedy. We thank University
Hospitals Coventry & Warwickshire NHS Trust,
Research Practitioners Susanne Armitage and Susan
Dale. Study conception and design: S.D., G.M.K. and
N.J.G. Questionnaire: G.M.K., N.J.G, C.M., F.H. and
S.D. Interviews: G.M.K., FH and N.J.G. Data entry:
G.M.K. Data analysis: G.M.K. and N.J.G. G.M.K. wrote
the first draft of the manuscript, N.J.G. and C.M. revised
the draft, and the other authors contributed to the final
draft and agree to be accountable for all aspects of the
work. G.M.K. has full access to all of the data and takes
responsibility for the integrity of the data and the accu-
racy of the data analysis.
Funding: This study was funded by Southend charity
group, and we thank the charitable committee.
Disclosure statement: The authors have declared no
conflicts of interest.
Data availability statement
The datasets generated during and/or analysed during
the current study are available from the corresponding
author on reasonable request.
Supplementary data
Supplementary data are available at Rheumatology
Advances in Practice online.
References
1 Armstrong AW, Schupp C, Bebo B. Psoriasis
comorbidities: results from the National Psoriasis
Foundation surveys 2003 to 2011. Dermatology 2012;
225:121–6.








ap/article/5/1/rkaa076/6081030 by guest on 09 June 2021
2 Dougados M, Soubrier M, Antunez A et al. Prevalence of
comorbidities in rheumatoid arthritis and evaluation of their
monitoring: results of an international, cross-sectional
study (COMORA). Ann Rheum Dis 2014;73:62–8.
3 Kaine J, Song X, Kim G, Hur P, Palmer JB. Higher
incidence rates of comorbidities in patients with psoriatic
arthritis compared with the general population using U.S.
administrative claims data. J Manag Care Spec Pharm
2019;25:122–32.
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